| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 08/02/2006 | EP1685251A2 Nucleic acid constructs |
| 08/02/2006 | EP1685223A1 Use of a solution comprising at least one nonionic surfactant |
| 08/02/2006 | EP1685160A1 Dry recombinant human alpha 1-antitrypsin formulation |
| 08/02/2006 | EP1685085A2 Implantable sensors and implantable pumps and anti-scarring agents |
| 08/02/2006 | EP1684894A1 Emulsion for conveying an active hydrophobic material to a substrate in an aqueous medium |
| 08/02/2006 | EP1684851A1 Methods for preparing polymeric buffer formulations for electrotransport applications |
| 08/02/2006 | EP1684846A1 Device for the transdermal administration of active ingredients |
| 08/02/2006 | EP1684820A2 Active agent delivery systems including a miscible polymer blend, medical devices, and methods |
| 08/02/2006 | EP1684794A1 Altering animal waste composition |
| 08/02/2006 | EP1684792A2 Pharmaceutical formulations for the sustained release of interleukins and therapeutic applications thereof |
| 08/02/2006 | EP1684769A2 Methods and formulations for the treatment of medical conditions related to elevated dihydrotestosterone |
| 08/02/2006 | EP1684767A1 Soft steroid compositions for use in dry powder inhalers |
| 08/02/2006 | EP1684761A1 Method and composition for treatment or prophylaxis of amyloidosis disorders |
| 08/02/2006 | EP1684760A1 Method and composition for treatment of cutaneous lesions |
| 08/02/2006 | EP1684748A2 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'(1h-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrozol-3-one choline |
| 08/02/2006 | EP1684739A1 Treatment and prevention of liver disease associated with parenteral nutrition (pn) |
| 08/02/2006 | EP1684734A2 Olanzapine containing transdermal drug delivery compositions |
| 08/02/2006 | EP1684733A1 G i tract delivery systems |
| 08/02/2006 | EP1684732A2 Ibuprofen-containing soft gelatin capsules |
| 08/02/2006 | EP1684731A1 Film-forming starchy composition |
| 08/02/2006 | EP1684730A1 Pharmaceutical composition having a cationic excipient |
| 08/02/2006 | EP1684729A2 Multilayer pharmaceutical dosage form containing a substance that acts in a modulatory manner with regard to the release of active substances |
| 08/02/2006 | EP1684728A1 Non-effervescent form of sodium naproxen comprising i.a. sodium hydrogen carbonate |
| 08/02/2006 | EP1684727A1 Macromolecular drug complexes having improved stability and therapeutic use of the same |
| 08/02/2006 | EP1684726A1 Composition and method for enhancing bioavailability |
| 08/02/2006 | EP1684725A1 Novel nimesulide compositions |
| 08/02/2006 | EP1684724A2 Enhanced drug delivery |
| 08/02/2006 | EP1684723A1 Contrast medium comprising liposomes containing hydrophobic chelate compound |
| 08/02/2006 | EP1684722A2 Medicamentously targeted local lipolysis |
| 08/02/2006 | EP1684721A2 Aerosol formulations comprising a carboxylic acid surfactant |
| 08/02/2006 | EP1684720A2 Introducing aerosol into a ventilator circuit |
| 08/02/2006 | EP1684719A2 Alpha 1-antitrypsin compositions and treatment methods using such compositions |
| 08/02/2006 | EP1684718A1 Methods of preparing a foam comprising a sclerosing agent |
| 08/02/2006 | EP1684717A2 Pharmaceutical aerosol compositions |
| 08/02/2006 | EP1684716A1 Dispersions and methods of preparing them |
| 08/02/2006 | EP1684715A2 Compositions comprising cyclohexylamines and aminoadamantanes |
| 08/02/2006 | EP1684714A2 Process for producing injectable gabapentin compositions |
| 08/02/2006 | EP1684713A1 Controlled release of topirimate in liquid dosage forms |
| 08/02/2006 | EP1684711A2 Composition |
| 08/02/2006 | EP1684704A2 Compositions and methods for increasing hdl and hdl-2b levels |
| 08/02/2006 | EP1684701A2 Compositions for achieving benefits in skin using key cellular metabolic intermediates |
| 08/02/2006 | EP1684691A2 Oral delivery system and method for making same |
| 08/02/2006 | EP1684689A2 Extended release venlafaxine formulation |
| 08/02/2006 | EP1684682A2 Reduction of unintended use of transdermal devices |
| 08/02/2006 | EP1684681A1 Transdermal high and low molecular weight compounds |
| 08/02/2006 | EP1503789A4 Vascularization enhanced graft constructs |
| 08/02/2006 | EP1496882B1 Tolterodine salts |
| 08/02/2006 | EP1492821B1 Iron dextrin compounds for the treatment of iron deficiency anaemia |
| 08/02/2006 | EP1481017B1 Biodegradable polymeric material for biomedical applications |
| 08/02/2006 | EP1455828B1 Photosensitizer functionalised nanoparticles |
| 08/02/2006 | EP1435971B1 Utilization of phosphatidylserine in the treatment of attention deficit syndrome (adhs) |
| 08/02/2006 | EP1395242B1 Liquid pharmaceutical composition |
| 08/02/2006 | EP1372737B1 Preparation for the prophylaxis of restenosis |
| 08/02/2006 | EP1341565B1 Drug delivery compositions and coated medical devices |
| 08/02/2006 | EP1328280B1 Composition for the treatment of dysglucaemia and method for the production of said composition |
| 08/02/2006 | EP1296656B1 Method for preparing a composition |
| 08/02/2006 | EP1296654B1 Use of dicalcium phosphate anhydride powder |
| 08/02/2006 | EP1272196B1 Methods of making the 4-n-butylcyclohexanoic and the undecanoic acid esters of (7 alpha,11 beta)-dimethyl-17 beta-hydroxy-4-estren-3-one and their medical use |
| 08/02/2006 | EP1267828B1 Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients |
| 08/02/2006 | EP1265598B1 Pharmaceutical composition for application to mucosal surfaces |
| 08/02/2006 | EP1212328B1 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 08/02/2006 | EP1133476B1 Iminoguanidine derivatives, preparation method, use as medicines |
| 08/02/2006 | EP1030662B1 Treatment of t-helper cell type 2 mediated immune diseases with retinoid antagonists |
| 08/02/2006 | EP0979243B1 Activation of peptides |
| 08/02/2006 | EP0939621B1 Inhibition of bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| 08/02/2006 | CN2801160Y Nanometer capsule contg deer antler and glossy ganoderma |
| 08/02/2006 | CN2801159Y Powder medicine patch packaged by immediate dissolution film |
| 08/02/2006 | CN2801158Y Wetting agent type medicinal plaster for preventing disease |
| 08/02/2006 | CN1812932A Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs |
| 08/02/2006 | CN1812814A Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| 08/02/2006 | CN1812813A Pharmaceutical compositions comprising peranhydrocyclodextrin |
| 08/02/2006 | CN1812793A Sustained drug-relase particles and process for producing the same |
| 08/02/2006 | CN1812783A Fluconazole containing capsules with improved active ingredient release |
| 08/02/2006 | CN1812781A Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences |
| 08/02/2006 | CN1812775A Method for inhibiting the growth of antibiotic-resistant of bacteria by using pentane-1,5-diol |
| 08/02/2006 | CN1812774A Nonaqueous pressure-sensitive adhesive for medicinal tape preparation for percutaneous absorption, medicinal tape preparation for percutaneous absorption, and process for producing the same |
| 08/02/2006 | CN1812773A Polyethylene oxide-based films and drug delivery systems made therefrom |
| 08/02/2006 | CN1812772A Microcapsules for the administration of active ingredients |
| 08/02/2006 | CN1812771A Subcutaneous implants having limited initial release of the active principle and subsequent linearly varying extended release thereof |
| 08/02/2006 | CN1812770A Use of ethanol as plasticizer for preparing subcutaneous implants containing thermolabile active principles dispersed in a PLGA matrix |
| 08/02/2006 | CN1812769A Tablets containing enrofloxacin and flavouring agents and/or flavours |
| 08/02/2006 | CN1812768A Pharmaceutical composition and method for treating |
| 08/02/2006 | CN1812767A Method for producing crystals from active ingredients in medicaments, crystals obtained therefrom and the use thereof in pharmaceutical formulations |
| 08/02/2006 | CN1812766A Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds |
| 08/02/2006 | CN1812765A Transmucosal form of administration with reduced mucosal irritation |
| 08/02/2006 | CN1812763A Nail restructuring compositions for topical application |
| 08/02/2006 | CN1812753A Drug releasing biodegradable fiber for delivery of therapeutics |
| 08/02/2006 | CN1810794A Prepn process and medicine composition of dewatered andrographolide |
| 08/02/2006 | CN1810291A Nasal cavity spraying inactivated influenza virus vaccine and its prepn process |
| 08/02/2006 | CN1810288A Nosebleeding treating glutinous rehmannia bolus |
| 08/02/2006 | CN1810286A Externally applied plaster |
| 08/02/2006 | CN1810285A Recipe and prepn of medicine for relieving asthma and cough |
| 08/02/2006 | CN1810282A Soft black bone chicken and white phoenix capsule and its prepn process and quality control method |
| 08/02/2006 | CN1810278A Enteric coated Chinese medicine composition for treating cervical and lumbar spondylopathy |
| 08/02/2006 | CN1810277A Chinese medicine composition for treating heart failure and its prepn process |
| 08/02/2006 | CN1810275A Pharyngitis treating ointment |
| 08/02/2006 | CN1810273A Rhinitis treating ointment |
| 08/02/2006 | CN1810271A Chinese medicine composition for treating apoplexy and its prepn process and use |
| 08/02/2006 | CN1810269A Freeze dried perhexiline powder for injection and its prepn process |
| 08/02/2006 | CN1810268A Apoplexy treating medicine composition |